|
End-of-day quote
Korea S.E.
2026-10-22
|
5-day change | 1st Jan Change | ||
| 194,300.00 KRW | -1.67% |
|
+6.70% | +12.72% |
| 12:50am | SK Securities Adjusts Celltrion's Price Target to 280,000 Won | MT |
| 10-22 | Celltrion Signs License-In Deal With Kaigene for KG013 Immune-Mediated Disease Drug Candidate | MT |
Company Valuation: Celltrion, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 27,592,583 | 23,000,359 | 27,970,378 | 40,365,453 | 39,602,284 | 44,384,833 | - | - |
| Change | - | -16.64% | 21.61% | 44.32% | -1.89% | 12.08% | - | - |
| Enterprise Value (EV) 1 | 27,117 | 23,236 | 29,280 | 41,531 | 42,173 | 46,024 | 45,658 | 44,731 |
| Change | - | -14.31% | 26.01% | 41.84% | 1.55% | 9.13% | -0.8% | -2.03% |
| P/E | 47.2x | 41.6x | 53.7x | 91.7x | 38.8x | 29x | 25.3x | 22.4x |
| PBR | 6.87x | 5.34x | 2.46x | 2.2x | 2.32x | 2.4x | 2.2x | 2.02x |
| PEG | - | -9.54x | -20.3x | -2.1x | 0x | 0.6x | 1.7x | 1.7x |
| Capitalization / Revenue | 14.6x | 10.1x | 12.9x | 11.3x | 9.51x | 7.94x | 6.97x | 6.29x |
| EV / Revenue | 14.3x | 10.2x | 13.5x | 11.7x | 10.1x | 8.23x | 7.17x | 6.34x |
| EV / EBITDA | 27.9x | 26.6x | 32.6x | 45.6x | 29x | 21.3x | 18.1x | 15.9x |
| EV / EBIT | 36x | 35.9x | 44.9x | 84.4x | 36.1x | 25.1x | 20.6x | 17.9x |
| EV / FCF | 46x | -211x | 89.5x | 54.2x | 78.4x | 40.4x | 34x | 28.6x |
| FCF Yield | 2.17% | -0.47% | 1.12% | 1.85% | 1.28% | 2.47% | 2.94% | 3.49% |
| Dividend per Share 3 | 628.9 | - | 436.1 | 686.8 | 714.3 | 727.7 | 780.6 | 818.1 |
| Rate of return | 0.38% | - | 0.25% | 0.4% | 0.41% | 0.37% | 0.4% | 0.42% |
| EPS 3 | 3,515 | 3,362 | 3,273 | 1,873 | 4,438 | 6,696 | 7,683 | 8,689 |
| Distribution rate | 17.9% | - | 13.3% | 36.7% | 16.1% | 10.9% | 10.2% | 9.41% |
| Net sales 1 | 1,891 | 2,284 | 2,176 | 3,557 | 4,162 | 5,590 | 6,367 | 7,056 |
| EBITDA 1 | 972.1 | 873.6 | 897.2 | 910.3 | 1,456 | 2,163 | 2,523 | 2,814 |
| EBIT 1 | 753.9 | 647.2 | 651.5 | 492 | 1,168 | 1,832 | 2,218 | 2,498 |
| Net income 1 | 575.1 | 533.2 | 535.6 | 422.7 | 1,030 | 1,557 | 1,774 | 1,999 |
| Net Debt 1 | -475.5 | 235.5 | 1,310 | 1,165 | 2,571 | 1,639 | 1,273 | 346.4 |
| Reference price 3 | 166,042.75 | 139,979.07 | 175,736.96 | 171,703.30 | 172,380.95 | 194,300.00 | 194,300.00 | 194,300.00 |
| Nbr of stocks (in thousands) | 166,178 | 164,313 | 159,160 | 235,088 | 229,737 | 228,435 | - | - |
| Announcement Date | 2/16/22 | 3/3/23 | 2/29/24 | 2/25/25 | 2/4/26 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 29.02x | 8.23x | 21.28x | 0.37% | 33.45B | |
| 18.38x | 6.48x | 12.88x | 1.62% | 63.29B | |
| 30.22x | 7.94x | 26.49x | 0.05% | 54.89B | |
| 36.58x | 6.5x | 19.41x | 0.88% | 53.28B | |
| 35.46x | 3.44x | 14.83x | -.--% | 45.81B | |
| 50.32x | 5.82x | 31.95x | -.--% | 43.46B | |
| -19.48x | 188.5x | -20.74x | -.--% | 40.23B | |
| 27.38x | 5.77x | 14.95x | -.--% | 23.7B | |
| 32.79x | 5.99x | 20.16x | -.--% | 23.76B | |
| -13.65x | 5.08x | -6.16x | -.--% | 22.53B | |
| Average | 22.70x | 24.37x | 13.50x | 0.29% | 40.44B | |
| Weighted average by Cap. | 24.46x | 24.37x | 14.70x | 0.41% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- A068270 Stock
- Valuation Celltrion, Inc.
Select your edition
All financial news and data tailored to specific country editions
